News & Publications
Press Release: Cambrian Biopharma Announces Licensing Agreement to Develop Selective mTOR Inhibitors
16
February
22
Press Release: Cambrian Biopharma Announces Licensing Agreement to Develop Selective mTOR Inhibitors
16
February
22
5 mins to read
19
April
22
Blog Post: Longevity Innovations vs. Moonshots
April 2022 blog post by Cambrian CEO James Peyer, PhD
See More
Visit
.svg)
5 mins to read
16
February
22
Press Release: Cambrian Biopharma Announces Licensing Agreement to Develop Selective mTOR Inhibitors
mTOR inhibitors prevent age-related physiologic decline and lengthen healthspan. Licensed compounds will be developed by new Cambrian subsidiary Tornado Therapeutics, led by Joan Mannick, M.D. as CEO.
See More
Visit
10 mins to read
6
January
22
Blog Post: The Secret Cambrian Bio Master Plan to Build Drugs to Treat Aging (just between you and me)
January 2022 blog post by Cambrian CEO James Peyer, PhD
See More
Visit
5 mins to read
26
October
21
Press Release: Cambrian Biopharma Closes $100 Million Series C to Advance Healthspan-boosting Therapeutics to the Clinic
Financing co-led by Anthos Capital and SALT Fund; Anthos’s Paul Farr and biotech leader Brent Saunders to join Board of Directors.
See More
Visit
5 mins to read
20
October
21
Juliette Han - The Top 25 Women Leaders in Biotechnology of 2021
Cambrian Biopharma Chief Operating Officer, Juliette Han, PhD named as one of the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report.
Visit
Visit
30 mins to watch
19
July
21
"Rational Mind" with Pietro Boselli - Episode 4: Longevity (featuring James Peyer)
"Rational Mind", a science series hosted by engineer and influencer Pietro Boselli, aims to inspire viewers to use rationality and critical thinking to approach complex issues. In this episode, James discusses the longevity science space and the opportunities and challenges ahead.
Visit
Visit
5 mins to read
15
July
21
James Peyer to present at the 8th Aging Research & Drug Discovery Meeting 2021
James Peyer to present new research in the biology of aging at the world's largest aging research for drug discovery conference.
Visit
Visit
45 mins to watch
16
June
21
CogX Festival 2021: "Death is just a Technical Problem" Panel Discussion with James Peyer
Does anyone really want to live until 180? Progress in longevity science is abundant at the moment, from healthspan hacking to novel therapies being brought under development. Our panel of experts discuss the philosophical and scientific innovations taking place at the cutting edge of the life-extensionists field and what implications they could have for us all.
Visit
Visit
15 mins to read
26
April
21
PM360: Cambrian is Using a New Drug Discovery Model to Solve the Science of Aging
Cambrian Biopharma is one of the newly emerging distributed drug discovery companies that applies a new twist to investing in interesting science. PM360 spoke with co-founder James Peyer about this new model, why he decided to focus on the biology of aging, and more.
Visit
Visit
75 mins to watch
14
April
21
Foresight Institute Biotech & Health Extension Webinar: “James Peyer: How to Fund and Build Geroprotectors”
In this session, James Peyer, PhD, CEO of Cambrian Biopharma, shares his overview of the longevity biotech industry with insights into what it actually means to be a longevity biotech company, how Cambrian functions, what is a "DisCo model" (and why it will most likely replace single asset biotech companies model), and the barriers preventing us from starting clinical trials with the first geroprotectors.
Visit
Visit
In the News
Bloomberg
22
April
22
The $7.6 Trillion Quest for Longer Life
The new field of longevity science aims to slow aging and make late-life more livable. But will the science ever work? And if so, will it only be for the super rich?
Visit
Fierce Biotech
26
October
22
Cambrian secures $100M series C for Roivant-like approach to biotech creation with goal to slow down human aging
Cambrian will likely test two of its first three compounds in rare childhood disorders "because the mechanisms work a little bit like fast-aging syndromes," said James Peyer, Ph.D., CEO and co-founder of the biotech.
Visit